The Complement System Study
The study drug is exploring a potential new treatment for complement pathway disorders.
This study is evaluating a new potential treatment for complement-mediated diseases. The complement system is a part of our immune system that helps protect us from infections. This study aims to assess the safety, tolerability, and pharmacokinetics (PK) of multiple subcutaneous (SC) doses in healthy participants. Currently, there are limited approved treatment options for diseases like Paroxysmal Nocturnal Hemoglobinuria (PNH) and other complement-mediated diseases.
By participating, you will contribute to meaningful research that could help shape future approaches to managing these conditions, making a positive difference for individuals and families affected by these challenges.
Call us on 1300 821 275 to discuss your eligibility today!